AstraZeneca, Amgen Announce Positive Phase III Brodalumab Study

By Dow Jones Business News, 
A A A


By Razak Musah Baba

LONDON--AstraZeneca PLC (AZN.LN) and Amgen Inc. ( AMGN ) said Monday that the Phase III AMAGINE-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.

The companies said a significantly higher proportion of patients treated with brodalumab achieved a PASI 75 response, or primary endpoint, as well as PASI 90 and PASI 100 responses at week 12, secondary endpoints, compared to a placebo.

"Data from the AMAGINE-1 study suggest that brodalumab may offer a new level of efficacy for patients with moderate- to-severe plaque psoriasis, a disease that affects more than 100 million people globally," said Sean E. Harper, executive vice president of research and development at Amgen.

"Moderate-to-severe plaque psoriasis is a serious disease, and despite available treatments, there is still a significant need for more effective therapies," Briggs Morrison, executive vice president of global medicines development at AstraZeneca, added.

Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


  (END) Dow Jones Newswires
  05-12-140239ET
  Copyright (c) 2014 Dow Jones & Company, Inc.


This article appears in: News Headlines

Referenced Stocks: AMGN

Dow Jones Business News


More from Dow Jones Business News:

Related Videos

How to Save Money at Bars
How to Save Money at Bars           

Stocks

Referenced

100%

Most Active by Volume

44,823,339
  • $75.19 ▲ 0.28%
43,744,171
  • $3.44 ▼ 0.29%
42,340,022
  • $97.671 ▲ 0.66%
34,178,145
  • $17.62 ▼ 1.23%
34,028,998
  • $15.59 ▼ 0.19%
32,055,708
  • $21.23 ▼ 2.41%
31,539,235
  • $3.76 ▲ 0.80%
30,434,619
    $34.25 unch
As of 7/25/2014, 04:03 PM